EXHIBIT 99
AMGEN INC.
FACTORS THAT MAY AFFECT THE COMPANY
Factors That May Affect the Company
Amgen operates in a rapidly changing environment that involves a number of risks, some of which are beyond the
Company's control. The following discussion highlights some of these risks and others are discussed elsewhere
herein.
Product development
The Company intends to continue an aggressive product development program. Successful product development
in the biotechnology industry is highly uncertain, and only a small minority of research and development programs
ultimately result in the commercialization of a product. Of the candidates that are selected for product
development, all will not be successfully commercialized. Product candidates that appear promising in the early
phases of development may fail to reach the market for numerous reasons, including, without limitation, results
indicating lack of effectiveness or harmful side effects in clinical or preclinical testing, failure to receive necessary
regulatory approvals, uneconomical manufacturing costs, the existence of third party proprietary rights, failure to
be cost effective in light of existing therapeutics, or other factors. There can be no assurance that the Company
will be able to produce future products that have commercial potential. Additionally, success in preclinical and
early clinical trials does not ensure that large scale clinical trials will be successful. For example, the Company has
previously announced product development failures in connection with BDNF (for subcutaneous injection for
ALS), a product candidate that did not produce acceptable clinical results in a specific indication with a specific
route of administration after a Phase III trial; although this product candidate had demonstrated acceptable
preclinical and earlier clinical trial results sufficient to warrant advancement to a later stage clinical trial. Further,
clinical results are frequently susceptible to varying interpretations which may delay, l